NewAmsterdam Pharma Co NV

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 29.58, 170.31, 423.65, 722.49, 1034.24 ], "ebit_estimate": [ -242.98, -211.04, -23.61, 265.53, 544.07 ], "ebitda_estimate": [ -227.74, 14.07, 340.27, 1384.8, 1617.7 ], "net_income_estimate": [ -221.26, -194.98, -3.74, 271.94, 546.84 ], "per_share_eps_estimate": [ -1.81, -1.58, -0.31, 1.51, 3.21 ], "eps_nri_estimate": [ -1.83, -1.56, -0.19, 1.51, 3.26 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -222.8, -194.98, -2.82, 282.74, 557.82 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -33.13, -22.65, 5.73, null, null ], "gross_margin_estimate": [ 100, 82.44, 90.32, 92.48, 94.25 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 23.39, 11.01 ], "long_term_growth_rate_mean": 49.11, "long_term_revenue_growth_rate_mean": "187.38", "future_per_share_eps_estimate_growth": 41.19, "future_eps_nri_estimate_growth": 49.11, "future_revenue_estimate_growth": 187.38, "future_ebit_estimate_growth": 49.91, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 70.24, "future_pretax_income_estimate_growth": 72.69, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -4.86, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 1.66, 7.67, 15.17, 3.5, 5.93, 35.25, 96.32, 22.06 ], "ebit_estimate": [ -66.1, -63.07, -60.52, -69.88, -69.84, -37.18, 26.89, null ], "ebitda_estimate": [ -66.2, -64.17, -51.22, null, null, null, null, null ], "net_income_estimate": [ -58.82, -57.86, -56.71, -65.34, -65.64, -33.3, 30.53, null ], "per_share_eps_estimate": [ -0.48, -0.48, -0.46, -0.56, -0.57, -0.34, 0.04, null ], "eps_nri_estimate": [ -0.49, -0.48, -0.46, -0.56, -0.57, -0.34, 0.04, -0.6 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -58.8, -57.85, -56.72, -65.34, -65.64, -33.3, 30.53, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 84, 89.5, 89.5, 86.5, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 49.11, "long_term_revenue_growth_rate_mean": "187.38", "future_per_share_eps_estimate_growth": 41.19, "future_eps_nri_estimate_growth": 49.11, "future_revenue_estimate_growth": 187.38, "future_ebit_estimate_growth": 49.91, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 70.24, "future_pretax_income_estimate_growth": 72.69, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -4.86, "future_operating_cash_flow_per_share_estimate_growth": null }